Jiangsu Hengrui Pharmaceuticals (01276): HRS-5635 injection is included in the list of breakthrough therapeutic varieties for public notification.
Hengrui Medicine (01276) announced that its subsidiary, Fujian Shengdi Pharmaceuticals Co., Ltd.'s HRS-56...
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary, Fujian Shengdi Medicine Co., Ltd., has had its HRS-5635 injection included in the National Medical Products Administration's list of proposed breakthrough therapy products for public notice, with a 7-day public notice period.
HRS-5635 injection is a new generation of liver-targeting siRNA drug developed independently by the company for HBV. The results of Phase II clinical trials of its monotherapy for chronic hepatitis B show that HRS-5635 has the potential to improve the functional cure of chronic hepatitis B and also has good safety characteristics.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
